Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Drug Cost Ratio in FY2009 was 22.3%, Up 1.1 Points from Previous Year: MHLW
June 8, 2012
- Local Governments Express Concern for IPV Price at 5,450 Yen
June 7, 2012
- Survey Highlights Successful Efforts of 5 Prefectures to Promote Generic Drug Use
June 6, 2012
- PAFSC 1st Committee on New Drugs Recommends Approval for Fibromyalgia Indication for Lyrica
June 5, 2012
- DPJ’s Proposal on 5-Year Innovation Strategy Calls for Subsidies to Reduce Consultation, Review Fees
June 4, 2012
- PAFSC’s 2nd Committee Recommends Approval for Pfizer Japan’s Axitinib
June 4, 2012
- MHLW Announces Addition of 5 APIs/8 Products to NHI Price List
June 1, 2012
- Cost-Effective Assessments “Not Appropriate” for Everything: MED Director Suzuki
May 31, 2012
- DPJ Proposal to Amend PAL Would Mandate Reporting of Package Inserts
May 31, 2012
- Specific Targets for New 5-Year Clinical Trial Activation Plan Expected by Late August
May 31, 2012
- Nakajima of HPB Calls on Kampo Association to Collect Data, Make Case for Favorable Re-Pricing
May 30, 2012
- MHLW Adds 8 APIs/10 Products Including Xalkori to NHI Price List
May 30, 2012
- MHLW Sets Up Office for Promotion of Medical Innovation to Realize New 5-Year Strategy
May 29, 2012
- MHLW Selects 5 Additional Clinical Research Core Hospitals
May 29, 2012
- AZ, Government Not Accountable in Iressa Appeal, Osaka High Court
May 29, 2012
- Chicken Pox, Mumps, and Adult Pneumococcal Vaccines to Be Added to Routine Vaccination Programs in FY2014 “at Earliest”: Dr Niki of DPJ
May 28, 2012
- CSIMC Expert Subcommittee Holds 1st Meeting on Cost-Effective Assessment; Members Urge Caution
May 25, 2012
- CSIMC Approves Listing for 8 APIs/10 Products; Peak Sales of Xalkori Expected to Reach 11.2 Billion Yen
May 25, 2012
- DPJ’s PAL Subcommittee Calls for Mandatory Submission of Package Inserts
May 24, 2012
- DPJ’s Committee Prepares Submission of Lawmaker-Initiated Bill to Create Third-Party Organization
May 24, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…